Lirentelimab
mAbexperimental
Clinical trial activity
14 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02808793)
Timeline
Indications
Mechanism of action
- Sialic acid-binding Ig-like lectin 8INHIBITOR
Sialic acid-binding Ig-like lectin 8 inhibitor
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSSWS48LJU3T ↗
- ChEMBLCHEMBL4297878 ↗
Also known as
- ak002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05528861 | Phase 2 | Oct 26, 2022 | Allakos, Inc. |
| NCT05155085 | Phase 2 | Dec 31, 2021 | Allakos, Inc. |
| NCT05152563 | Phase 3 | Dec 31, 2021 | Allakos, Inc. |
| NCT04856891 | Phase 3 | May 20, 2021 | Allakos, Inc. |
| NCT04620811 | Phase 3 | Dec 3, 2020 | Allakos, Inc. |
| NCT04322708 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2020 | Allakos, Inc. |
| NCT04322604 | Phase 3 | Mar 31, 2020 | Allakos, Inc. |
| NCT04324268 | Phase 1 | Mar 23, 2020 | Allakos, Inc. |
| NCT03664960 | Phase 2 | Nov 30, 2018 | Allakos, Inc. |
| NCT03496571 | Phase 2 | Jul 18, 2018 | Allakos, Inc. |
| NCT03379311 | Phase 1 | Feb 26, 2018 | Allakos, Inc., Stanford University |
| NCT03436797 | Phase 2 | Jan 23, 2018 | Allakos, Inc. |
| NCT02859701 | Phase 1 | Aug 1, 2016 | Allakos, Inc., Nucleus Network Ltd |
| NCT02808793 | Phase 1 | Jun 1, 2016 | Allakos, Inc. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allakos, Inc. | For profit | 14 | 14 | 3 | 2016 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1